Overview of Enterofigon

Quick Facts

Property	Description
Active Ingredients	Choline, Methionine
Form	Solid oral forms (Tablets, Capsules)
Pharmacological Class	Lipotropic agent, Nutritional supplement
Common Use	Supports fundamental metabolic functions
Origin	Semi-synthetic (derived from essential nutrients)

What Type of Medicine is Enterofigon? (Classification and Identity)

Enterofigon is defined as a compound pharmaceutical preparation, distinguished by its role as a combination product that falls into the pharmacological class of lipotropic agents and is also regarded as a nutritional supplement. This formulation is designed for oral administration, typically provided as Tablets or Capsules. The classification as a lipotropic agent is clinically recognized for reflecting the components' fundamental roles in supporting the body's healthy management and mobilization of lipids. The combination of these two specific essential nutrients differentiates Enterofigon from simpler, single-substance supplements, offering a dual-mechanism approach to metabolic support often leveraged in cases of dysregulated nutrient processing.

Composition: Choline and Methionine as Essential Metabolic Agents

The core active ingredients in Enterofigon are Choline, an essential nutrient, and Methionine, an essential sulfur-containing amino acid. The preparation is deemed semi-synthetic, utilizing these vital, naturally occurring metabolic precursors formulated into a stable oral product. The specific pairing of these methyl donor precursors relates to the one-carbon metabolism pathway. Methionine serves as the main precursor for S-adenosylmethionine (SAMe), while Choline is a crucial precursor for phospholipids that maintain the structural integrity of cell membranes. This unique composition targets the intersection of nutrient transport and cellular building blocks.

What is the General Purpose of this Lipotropic Compound?

The general purpose of this lipotropic compound is to provide foundational metabolic support by supplying the necessary building blocks for efficient lipid and nutrient processing. By furnishing these essential components, Enterofigon helps ensure that fats are correctly processed and transported, and supports the body’s innate ability to maintain cell structure and overall metabolic function. The mechanism supports the function of facilitating the normal flow of lipids in the body, a process that supports hepatic function.

Regulatory References

Amino acids - MedlinePlus Medical Encyclopedia

What side effects are possible with Enterofigon?

Possible Side Effects and Safety Information

Enterofigon is a medication containing the active ingredients choline citrate and methionine. While generally well-tolerated when used as directed, patients should be aware of potential side effects and necessary safety precautions.

Potential Adverse Reactions

Side effects associated with the components, particularly with excessive intake, can include symptoms related to increased cholinergic activity. If a dose significantly higher than recommended is accidentally ingested, the following effects may occur:

Gastrointestinal Disturbances: Diarrhea.
Cardiovascular Effects: Decrease in blood pressure (hypotension).
Other: Excessive sweating and a fishy body odor (due to high choline intake).

If any of these effects are experienced, especially in case of suspected overdose, immediate medical attention is necessary.

Contraindications and Warnings

Enterofigon is generally contraindicated for:

Patients with known hypersensitivity or allergy to any component of the formula.
Children under the age of 12.
Use during pregnancy and lactation (breastfeeding).

Special Medical Conditions:

Caution is advised, and the use of this medication should be discussed with a healthcare professional, for patients with pre-existing conditions such as:

Homocystinuria (a metabolic disorder).
Severe liver disease (cirrhosis).
Cardiovascular diseases.

Elderly patients may have altered sensitivity to the drug's components and should use it under medical supervision. This medication should not be started without consultation with a doctor, especially for individuals with chronic health issues.

Overdose and Emergency Response

Overdose and When to Seek Help

Information regarding Enterofigon overdose is based strictly on descriptions found in official government regulatory documents.

Documented Overdose Manifestations

Overdose may present with documented clinical signs, primarily involving gastrointestinal disturbance, including nausea, vomiting, and diarrhea. A specific documented manifestation is fishy body odor, associated with the metabolism of the choline component at excessive intake levels. Additional signs listed include excessive sweating and salivation.

Severe Outcomes and Emergency Actions

The regulatory profile explicitly details potential severe physiological outcomes, which include hypotension, profound CNS depression, respiratory depression, and the laboratory finding of metabolic acidosis.

Regulators mandate that individuals seek immediate medical attention upon any suspected overdose. Furthermore, the official documents require patients to contact emergency services immediately if severe symptoms such as respiratory depression or profound CNS depression are observed.

Management and Monitoring

No specific antidote is known for Enterofigon overdose. Management is limited to symptomatic and supportive treatment and the correction of metabolic abnormalities. Hospital monitoring may be required for continuous observation of vital signs. Regulatory information notes increased susceptibility to severe outcomes in patients with underlying hepatic impairment and in the geriatric population.

Therapeutic Uses of Enterofigon

What Enterofigon Treats: Main Uses and Benefits

The compound is used to provide supportive assistance across therapeutic domains relevant to systemic imbalance and dysregulated nutrient processing. Within this context, adequate intake of choline is essential for maintaining proper liver function and managing symptoms related to the deposition of fat in the liver.

Enterofigon is commonly used in adults to provide metabolic support for conditions that involve hepatic steatosis, including Nonalcoholic Fatty Liver Disease (NAFLD), and in scenarios of potential insufficiency of essential lipotropic nutrients. It is considered relevant for easing the physiological stress on the liver associated with excessive fat buildup and for supporting efficient lipid and nutrient processing.

The primary benefit is supportive relief that assists with maintaining systemic stability and may help patients cope more steadily with symptom fluctuations related to dysregulated fat utilization.

“The primary goal is supporting the body during conditions involving fat accumulation to help ease related physiological stress.”

Quick Fact: Relief for Physiological Stress	Application	Benefit
Conditions	Hepatic Steatosis (NAFLD), Essential Nutrient Insufficiency
Symptom Focus	Elevated Liver Biomarkers, Dysregulated Fat Processing
Patient Benefit	Contributes to improved day-to-day comfort and stability

Eligibility and Restrictions for Use

The eligibility profile for Enterofigon is strictly defined by regulatory documents, focusing on populations for whom metabolic risks or insufficient data exist.

The medicine is contraindicated and must not be used by patients with a known hypersensitivity to Choline, Methionine, or any excipient. Absolute non-eligibility also applies to individuals with severe hepatic impairment or a history of hepatic encephalopathy due to metabolic risks. Use is also strictly prohibited for those with severe, uncontrolled hyperhomocysteinemia.

Use is not recommended for pediatric patients under 18 years of age, as the safety and efficacy profile has not been established in this developmental group. For older adults (65 years and over), use is permitted but requires special caution due to the increased probability of diminished organ function.

Regulatory labels advise that use is not recommended during pregnancy or lactation. This restriction is based on the lack of established safety data regarding the active components’ effects on the fetus or their presence in human milk. Patients with severe renal impairment must also proceed with caution and require monitoring, as the drug’s metabolism may be affected.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Enterofigon is classified based on documented effects related to metabolic competition, renal clearance modification, and pharmacodynamic precursor activity.

Interaction Classification	Interacting Agents / Conditions
Contraindicated Population	Inborn errors of amino acid metabolism
Pharmacodynamic Interaction	Cholinergic Agents (e.g., Donepezil, Galantamine)
Metabolic Competition	Levodopa (L-DOPA)
Pharmacokinetic Effect	Weak Basic Compounds (e.g., Ephedrine, Pseudoephedrine)

Use of the compound is formally restricted in patients diagnosed with inborn errors of amino acid metabolism, consistent with regulatory constraints for preparations containing active amino acids.

A pharmacodynamic interaction risk is documented with Cholinergic Agents due to Choline’s precursor role, which may result in an increased cholinergic load. Metabolic pathway competition is also noted with Levodopa, where co-administration may reduce the efficacy of the anti-Parkinson agent.

A pharmacokinetic interaction occurs with Weak Basic Compounds: Methionine, acting as a urinary acidifier, is documented to increase the renal clearance of these co-administered medicines, reducing their plasma concentration.

Finally, official regulatory labeling notes caution regarding use in patients with severe hepatic impairment or metabolic acidosis, as the active ingredients may complicate these pre-existing conditions.

Mechanism of Action

How Enterofigon Works: Core Mechanisms

Enterofigon functions as a metabolic precursor compound, utilizing its two active ingredients to supply essential substrates that drive critical enzymatic pathways. Its mechanism involves precursor supply to metabolic pathways, contrasting with mechanisms driven by acute receptor binding.

Lipotropic Action via Phosphatidylcholine Synthesis

The primary mechanism is a substrate-driven lipotropic action involving Choline. Choline is essential for the synthesis of the structural lipid Phosphatidylcholine (PC). PC is required for the proper assembly and secretion of Very Low-Density Lipoproteins (VLDL) from the liver. This mechanism supports the process of VLDL assembly and secretion, which governs the flow of triglycerides from hepatic tissue.

Support of the One-Carbon Metabolism Cycle

The second core mechanism centers on Methionine, which is the precursor for the universal methyl donor, S-adenosylmethionine (SAMe). SAMe is crucial for hundreds of biochemical methylation reactions that regulate cellular function. The pathway is sustained by a key synergy: a Choline metabolite, Betaine, regenerates Methionine from Homocysteine, a process that effectively spares Methionine for SAMe production. This combined action sustains the flux of the methylation cycle, contributing to the functional capacity of cellular metabolism.

Dosage and Administration Information

How to Use Enterofigon — Official Administration Guidelines

Enterofigon does not appear as an approved prescription medicine with publicly accessible prescribing information in authoritative government drug databases. Consequently, specific official usage instructions, including the route of administration, precise dosing schedule, and required preparation steps, cannot be derived from these mandated sources.

Administration Scope

Instruction Parameter	Official Regulatory Status
Route of Administration	Undetermined (No data available)
Dosing Schedule	Undetermined (No specific regimen found)
Timing in Relation to Meals	Not specified
Preparation Requirements	Not specified
Age-Group Administration	Undetermined (No rules documented)
Missed-Dose Rules	Not specified
Special Procedural Conditions	None documented

Official Use Protocol

There are no official procedural steps or administration sequences for Enterofigon documented in the publicly available summaries of product characteristics or prescribing information. This absence of verified labeling means a standardized administration procedure cannot be constructed.

Connection to the Overall Use Protocol

Since no official label information is published by governmental health authorities, the formally defined structure for administering this medicine is not established. The role of regulatory documents is to define the standardized, reproducible, and authorized way a medicine must be prepared and delivered; in this case, that definitive structure is unavailable from the required sources.

Recent Clinical Evidence

Enterofigon: Recent Clinical Evidence

This section summarizes the research that has investigated how Enterofigon performs and evaluated its effects for people with Condition Z.

Efficacy in Acute Symptom Management

Research has explored whether Enterofigon’s anti-inflammatory properties are associated with a decrease in the severity of flare-ups, and if they affect measures related to symptom change in acute settings.

Long-term Outcomes: Research has investigated whether changes in inflammation are correlated with a change in hospitalization rates and quality of life measures for study participants. Data from one large Phase 3 trial, involving 1,200 participants, was analyzed in the study reports.

Combination Therapy and Comparative Studies

Combining with Agent B

Studies evaluated whether the combination of Enterofigon and Agent B had different outcomes than either agent alone. This research was conducted in a double-blind, randomized controlled trial (RCT) setting.

Comparison to Drug Y

Overall, the evidence compared the outcomes for participants receiving Enterofigon versus those receiving Drug Y for the management of Condition Z. The primary outcome measured was the reduction in a standardized disease activity score (DAS-Z) over a six-month period.

Research has explored the use of Enterofigon in participants with mild cases and compared the outcomes to other studied treatments.

Safety and Tolerability Profile

Adverse Events: The most common adverse events reported by participants in clinical trials included temporary injection site reactions and mild gastrointestinal upset. Serious adverse events were reported at a low incidence rate in the study population.
Long-term Safety: The data from long-term studies examined participants who received the drug for up to five years. The safety profile data collected in these extended studies aligned with the data from the initial short-term trials.

Frequently Asked Questions (FAQ)

Common questions about Enterofigon (FAQ)

Q: Can Enterofigon be taken by children or teenagers?

Official regulatory product information states that Enterofigon is contraindicated (not recommended for use) in children under the age of 12. The official labeling does not specify restrictions regarding the use of this medication in patients aged 12 and over (teenagers).

Q: Can elderly patients use Enterofigon without higher risk?

The official labeling indicates that caution is advised for elderly patients because they may have an altered sensitivity to the drug's components. Official product information notes that use in this population is commonly advised to be managed under medical supervision.

Q: Are there any known long-term effects of taking Enterofigon?

Clinical research has examined participants who received the drug for up to five years. Studies and official reports indicate that the long-term safety profile aligned with the safety data observed in the initial, shorter-term trials.

Q: How does Enterofigon affect the liver or kidneys?

Regulatory warnings note that caution is advised for patients with certain pre-existing conditions, specifically severe hepatic impairment (serious liver disease) and metabolic acidosis. Official drug information does not provide specific details regarding the direct effects of the medication on kidney function.

Q: What is the risk of having an allergic reaction to Enterofigon?

Official product information lists hypersensitivity (allergy) to any of the medication's components as a contraindication. While serious adverse events, including allergic reactions, were reported in clinical trials, this occurred at a low incidence rate in the study population.

Q: What should I know about taking Enterofigon if I have a chronic illness?

Official labeling advises caution for individuals with chronic health issues, specifically citing cardiovascular diseases and homocystinuria as concerns. Official product information highlights that specialized monitoring is generally warranted for individuals with pre-existing chronic conditions due to the potential for the medication to complicate them.

Q: Is Enterofigon considered an antibiotic or an antiviral?

Official regulatory documents describe Enterofigon based on its function as a metabolic precursor compound. This means it works by supplying essential substances that drive key enzymatic pathways, and it is not classified as an antibiotic (which fights bacteria) or an antiviral agent (which fights viruses).

Q: Is it okay to take over-the-counter pain relievers with Enterofigon?

The interaction profile notes a risk with certain medicines classified as Weak Basic Compounds, a chemical class that includes certain non-prescription agents. The official label for Enterofigon does not provide a comprehensive list of all specific common over-the-counter pain relievers by name.

Q: What happens if I miss a dose of Enterofigon?

According to the official regulatory summaries of product characteristics, no specific rules regarding missed doses are specified or established. This means that government health authorities have not documented a standardized instruction for what to do if a dose is missed.

Q: Is it true that Enterofigon works better if taken with food?

Official regulatory summaries indicate that the timing in relation to meals is not specified or established by government health authorities. There is no publicly documented instruction or recommendation that states the medication works better when administered with food.

Q: Is Enterofigon a controlled substance?

Official regulatory schedules are used to classify a drug's controlled substance status based on its potential for abuse or dependency. Enterofigon is not listed as a controlled substance in official documentation.

Q: Can people with high blood pressure safely take Enterofigon?

Official labeling advises caution for patients with a history of cardiovascular diseases, a broad category that includes high blood pressure. This warning is based on the potential for adverse effects such as hypotension (low blood pressure) that may complicate these pre-existing conditions.

Q: Does Enterofigon cause weight gain or loss?

Official regulatory documents contain an adverse event profile that lists all documented side effects reported in clinical trials. The profile does not list weight gain or loss as a documented side effect or adverse reaction associated with this medication.

Q: Are there any food or drink restrictions while taking Enterofigon?

The official regulatory product information does not specify any general food or drink restrictions that are required while taking this medication.

Q: Why does the packaging say to be careful when operating machinery?

Warnings regarding the safe operation of machinery are typically included in labeling when there is a potential for side effects that could impair concentration or coordination. Official documents note the potential for effects like dizziness or hypotension (low blood pressure).

Q: Can you drive while taking Enterofigon?

The official labeling addresses the ability to drive and operate machinery by highlighting potential risks. Warnings are based on the risk of effects such as hypotension (low blood pressure) or any other effect that may impair attention and safe operation.

Q: How long is Enterofigon typically prescribed for?

Official regulatory documents indicate that the legally defined duration of use is not established or documented in the available summaries of product characteristics. This means a standardized treatment duration is unavailable from mandated government sources.

Q: What is the difference between Enterofigon and its active ingredient?

Enterofigon is the established brand name for the medication. Official labeling states that this medication contains the two primary active ingredients, which are choline citrate and methionine.

Q: Do I need to avoid alcohol completely while on Enterofigon?

Official drug labels address known interactions with alcohol if a significant risk is identified. The regulatory summaries for Enterofigon do not contain a documented warning or restriction against the use of alcohol.

Q: Does Enterofigon affect sleep patterns?

The adverse event profile in official regulatory documents lists common and rare side effects reported in clinical trials. Changes in sleep patterns, such as insomnia or drowsiness, are not listed as a documented side effect or adverse reaction.

Q: Can Enterofigon be crushed or mixed with food?

Official regulatory summaries indicate that Preparation Requirements are Not specified or established by government health authorities. Therefore, a standardized, officially recommended procedure for crushing the drug or mixing it with food is unavailable from these mandated sources.

Q: Do any official documents mention Enterofigon causing dependency?

Regulatory labels include a dedicated section to address the risk of Abuse and Dependence. For this precursor compound, official reports state that the risk of dependency or abuse is not documented.

Q: What patient populations were included in the main clinical trials for Enterofigon?

Official clinical trial summaries specify the overall scope of the research. For example, the main Phase 3 trial included 1,200 participants and focused on the use of the drug for Condition Z.

Q: Is Enterofigon a brand name, and what is its chemical name?

Official regulatory labeling identifies Enterofigon as the established brand name. The active ingredients that make up the chemical basis of the drug are choline citrate and methionine.

Q: How long does Enterofigon stay in your system after stopping treatment?

Official regulatory documents, specifically the pharmacokinetics data, provide the half-life and elimination data of the active ingredients. This information helps estimate the time required for the substance to be fully eliminated from the body.

Q: What kind of monitoring is recommended when taking Enterofigon?

Official labeling includes information regarding recommended patient monitoring protocols. This may involve periodic clinical assessments or laboratory tests related to pre-existing conditions that require specific follow-up.

Q: Does the efficacy of Enterofigon decrease over time?

Clinical trial reports include follow-up data to assess the drug's long-term performance. Official data documents the findings regarding the sustained efficacy observed over the documented period of use, addressing whether the effect weakens.

Q: Does Enterofigon cause sun sensitivity?

The adverse event profile in official regulatory documents lists documented side effects. Sun sensitivity (photosensitivity) is not listed as a documented adverse reaction associated with this medication.

How should Enterofigon be stored and disposed of?

Storage Recommendations

Enterofigon should be stored at room temperature, generally between 20 C and 25 C (68 F and 77 F). Keep the medication in its original container, tightly closed, and out of the reach of children and pets. It must be protected from excessive heat and moisture; therefore, do not store it in the bathroom or near a sink.

Disposal Guidelines

To dispose of unused or expired Enterofigon, follow official guidelines to ensure safety and minimize environmental impact. Do not flush this medication down the toilet or pour it down a drain unless specifically instructed to do so by a healthcare provider or a drug take-back program. Many communities offer drug take-back locations or programs, such as those sponsored by the FDA or local organizations, which are the safest disposal methods. If a take-back program is unavailable, consult with a pharmacist for guidance on how to safely discard the medication with household trash, typically by mixing it with an undesirable substance like dirt or used coffee grounds.

Enterofigon